Chimeric Antigen Receptor T-Cell Therapy: A Cure for Cancer?
This activity consists of recorded presentations from the "27th Annual National Conference" held Oct. 15–17, 2018, in Minneapolis, Minn.
Chimeric antigen receptor (CAR) T-cell therapy is a novel immuno-oncology treatment that has the potential to revolutionize cancer treatment. It is an area that is expanding quickly—the first two CAR-T cell therapies were approved in 2017 and there are now over 200 ongoing clinical trials, of which 50 were added in 2016 alone. While the majority of CAR T-cell therapy studies involve B-cell malignancies, this treatment is being investigated in solid tumors as well. While CAR T-cell therapy is highly effective against relapsed/refractory (R/R) malignancies, serious toxicities present an important treatment challenge. This presentation will provide an overview of how CAR T-cell therapy works, review the most common and potentially lethal toxicities associated with CAR T-cell therapy and discuss future directions in this field.
This activity is provided by OptumHealth Education.
There was no commercial support received for this activity.
To view this activity, you will need Internet Explorer 7.0+ or Firefox 3.0+ with Windows Media Player 9+, RealPlayer 12+ or Adobe Flash Player 9+. Be sure to disable any pop-up blocking software prior to beginning this activity.
This activity is designed to meet the educational needs of case managers, nurses, pharmacists, pharmacy technicians, physicians and other health care professionals who are interested in CAR T-cell therapy.
At the end of this educational activity, participants should be able to:
- Identify the currently available and emerging CAR T-cell therapies for R/R malignancies.
- Explain how CAR T-cell therapy works.
- Describe the most common and potentially lethal toxicities associated with CAR T-cell therapy and strategies for their management.
- Discuss potential future directions of CAR T-cell therapy.
- State the logistical requirements for and barriers to adopting CAR T-cell therapy in clinical practice.
Michael R. Bishop, MD
Michael Abecassis, MD, MBA
J. Roscoe Miller Distinguished Professor
Departments of Surgery and Microbiology/Immunology
Feinberg School of Medicine, Northwestern University;
Chief, Division of Organ Transplantation
Northwestern Memorial Hospital;
Founding Director, Comprehensive Transplant Center
Sarah Chart, RN
Eden Prairie, MN
Dixon B. Kaufman, MD, PhD, FACS
Ray D. Owens Professor of Surgery
Chief, Division of Transplantation
University of Wisconsin School of Medicine and Public Health;
Rebecca Gleason, RN, CCM
Eden Prairie, MN
Tina Rydland, PharmD
Crystal Clear Rx
Crystal Wong, MD
President Propoint Medical Writing
Disclosures of relevant financial relationships
In accordance with the ACCME Standards for Commercial SupportSM, OptumHealth Education (OHE) requires all those involved in the development of activity content to disclose their relevant financial relationships. An individual has a relevant financial relationship if such person (or his/her spouse/partner) has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services relate to the activity content. OHE ensures that the content is independent of commercial bias.
Dr. Bishop has indicated that he is on the speakers’ bureau for Agios and Celgene; consultant/advisory board member of CRISPR, Juno and Novartis; and consultant/advisory board/speakers’ bureau member of Kite/Gilead.
Ms. Chart and Ms. Gleason have indicated that they are employees of and own stock in UnitedHealth Group.
Dr. Wong has indicated that she has received grant/research support from MyoKardia.
The remaining activity faculty or planners have no financial relationships to disclose.
Method for calculating CE credit
CE credit was calculated by the complexity of content.
In support of improving patient care, OptumHealth Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the health care team.
Credit Designation Statements
The participant will be awarded up to 1.00 contact hour(s) of credit for attendance and completion of supplemental materials.
The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts credit from organizations accredited by the ACCME and ANCC.
This activity is approved for 1.00 contact hour(s) ([0.10] CEU) in states that recognize ACPE.
Attending the full program will earn 1.00 contact hour(s).
Unique Activity Number(s): JA0007123-0000-19-024-H01-P/T
OptumHealth Education designates this enduring activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The American Academy of Physician Assistants (AAPA) accepts credit from organizations accredited by the ACCME.
The Commission for Case Manager Certification has approved this program for a maximum of 1.00 clock hour(s) for Certified Case Managers (CCM).
A certificate of attendance will be provided to learners upon completion of activity requirements, enabling participants to register with licensing boards or associations that have not been preapproved for credits. To apply for credit types not listed above, participants should use the procedure established by the specific organization with which they wish to obtain credit.
- 1.00 ACPE - Pharmacist
- 1.00 ACPE - Pharmacy Technician
- 1.00 AMA
- 1.00 ANCC
- 1.00 Attendance
- 1.00 CCMC - General
You must be logged into your account to participate in this activity. Get started by clicking “Begin/Continue” and viewing the “CE Info”; then follow the prompts at the bottom of the screen. At the end of the activity, you will be able to view, save or print your certificate of participation. A complete listing of all of your activities can be found under “My Account”, “My Activities.”